Ifinatamab Deruxtecan Receives Breakthrough Therapy Designation from FDA for Pretreated Extensive-Stage Small Cell Lung Cancer The oncology research landscape took a significant step forward this week with the announcement that ifinatamab deruxtecan (I-DXd), an investigational antibody-drug conjugate (ADC), has been…
Grove Biopharma to Showcase Breakthrough Bionic Biologics™ at ACS Fall 2025 Symposium on Materials Biology Grove Biopharma, a private biotechnology company advancing an innovative therapeutic approach it calls Bionic Biologics™, announced that it will present updates on its research at…
AstraZeneca Launches FluMist Home: First Nationwide At-Home Delivery Service for Needle-Free Influenza Vaccination AstraZeneca has announced the launch of FluMist Home, a pioneering direct-to-consumer initiative that will allow individuals and families in much of the United States to receive FLUMIST®…
Nu-Tek BioSciences to Showcase 100% Animal-Free Peptones and Yeast Extracts at BPI East 2025, Driving the Future of Sustainable Cell Culture and Fermentation In an era where biopharmaceutical manufacturers are under increasing pressure to innovate while adhering to higher safety,…
Pfizer and Astellas Announce Landmark Phase 3 Results for PADCEV™ Plus KEYTRUDA™ in Muscle-Invasive Bladder Cancer, Marking Potential Paradigm Shift in Treatment for Cisplatin-Ineligible Patients Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura)…
Stoke Therapeutics and Biogen Dose First Patient in Pivotal Phase 3 EMPEROR Study of Zorevunersen, an Investigational Disease-Modifying Therapy for Dravet Syndrome Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering RNA-based medicines to restore protein expression, and Biogen Inc.…
Melinta Therapeutics to Be Acquired by CorMedix in $300 Million Deal, Marking a Major Milestone in the Acute Care Pharmaceutical Sector Melinta Therapeutics, LLC (“Melinta”), a leading commercial-stage pharmaceutical company known for delivering innovative therapies for acute and life-threatening illnesses,…
Bora Pharmaceuticals Unveils Multi-Year Expansion of Maple Grove Site as U.S. Growth Strategy Advances Post-Upsher-Smith Split Bora Pharmaceuticals Co., Ltd. (TWSE: 6472), a leading global contract development and manufacturing organization (CDMO), has formally launched a multi-year investment plan to significantly…
U.S. Hospitals Achieve Significant Gains in Surgical Patient Outcomes Since 2019, AHA and Vizient Report Shows In a compelling new report released jointly by the American Hospital Association (AHA) and Vizient®, researchers have found that outcomes for hospitalized surgical patients…
Navitus and Costco Pharmacy Partner to Transform Drug Pricing Transparency with Cost-Plus Model Launching in 2026 In a bold move aimed at reshaping the landscape of prescription drug pricing in the United States, Navitus Health Solutions, the nation’s first and…
Arrowhead’s Subsidiary Visirna Transfers Greater China Rights to Plozasiran to Sanofi in Strategic $395 Million Deal Amid Regulatory Milestone in Hypertriglyceridemia In a move poised to reshape the therapeutic landscape for patients with severe lipid disorders in China, Arrowhead Pharmaceuticals,…
BeOne Medicines Achieves Key Regulatory Milestone as EMA Grants PRIME Designation to BTK Degrader BGB-16673 for Waldenstrom’s Macroglobulinemia BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), an emerging global player in oncology therapeutics, has reached a critical milestone in…